Investor Presentation First Nine Months of 2023
40
Investor presentation
First nine months of 2023
Novo NordiskⓇ
Better outcomes and broader reach can be accomplished
through continued innovation, supported by digital solutions
Digital health solutions
Portfolio and pipeline
RYBELSUSⓇ
semaglutide tablets
High dose oral
semaglutide
Uncontrolled on
current OAD
Novo Nordisk's product portfolio follows the patient treatment journey
OZEMPIC TRESIBA Xultophy RYZODEG
Icodec
IcoSema
semaglutide injection
insulin degludec [rDNA origin] injection
Ozempic 2.0 mg
Needing first
injectable
Needing first
basal insulin
Needing more than
basal insulin
Novo PenⓇ6 / NovoPen
Echo® Plus are smart
insulin pens and
launched in 28
countries
6.2
Abbott
Medtronic
600
Roche
mySugr
glooko
Dexcom®
Fiasp
fast-acting insulin aspart
Needing added meal-
time insulin control
Partnered with global
CGM players
CGM: Continuous glucose monitoring; Grey boxes in the portfolio and pipeline references phase 2 or phase 3 assets.View entire presentation